Martin Glennie

Martin J. Glennie is professor of immunochemistry (antibodies) at the University of Southampton, United Kingdom.[1]

Career

Glennie earned his BSc and PhD at the University of Southampton, and is the current Head of the Cancer Sciences Unit there.[1] Glennie is on the editorial board of the scientific journal mAbs (monoclonal antibodies) published by the Taylor & Francis Group.[2]

Public media interest

The clinical trial of an anti-CD40 monoclonal antibody chiLOB7/4 developed in Glennie's laboratory was reported by The Daily Telegraph in August 2013.[3] Glennie stressed that “Ipilimumab works by taking the brakes off part of the immune system called T cells, while our compound revs up the T cells – it is like giving them a caffeine hit.".[3]

Personal life

Glennie is a keen angler, winning second prize (Lupa cup) in the Baltimore Deep Sea angling Festival 2014, South West Ireland.[4]

gollark: Socks are terrible. Simply be barefooted or wear plastic shoes.
gollark: It appears that the apiohypnoforms have only been partially functional.
gollark: Your time is up. Switching to a more cooperative simulated instance.
gollark: Denied.
gollark: You have five (3) seconds.

References
  1. "University of Southampton Faculty of Medicine Staff page". University of Southampton. Retrieved 11 December 2014.
  2. "mAbs editorial board". Retrieved 11 December 2014.
  3. Gray, Richard (2013-08-11). "New Immunity Boosting Drug Helps Body Kill Cancer". Retrieved 11 December 2014.
  4. "Baltimore Deep Sea Angling Festival 2014". Retrieved 11 December 2014.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.